Jetrea ocriplasmin: Phase IV start

This month, ThromboGenics will begin the observational, U.S. Phase IV ORBIT trial to evaluate Jetrea in a "real-world setting" in 1,500 patients with symptomatic VMA and VMT. Jetrea is marketed in the...